The Role of Amylin in Bone Metabolism

Exclusion Criteria

• •Anaemia (haemoglobin below normal range)
• •Liver disease (ALAT and/or ASAT \>2 times normal values) or history of hepatobiliary disorder
• •Nephropathy (eGFR \<60 ml/min/1,73m2 and/or microalbuminuria)
• •Microvascular complications except non-proliferative retinopathy
• •Treatment with anti-osteoporosis medication or glucocorticoids
• •Fractures within the last 6 months
• •For women: currently perimenopausal or postmenopausal
• •Diseases affecting calcium metabolism (e.g. hypoparathyroidism, hyperparathyroidism, osteoporosis, vitamin D deficiency and cancer)
• •Pregnancy or breastfeeding
• •Any physical or psychological condition that the investigator feels would interfere with trial participation
• •Treatment with any glucose-lowering drugs beside insulin, treatment with medication against osteoporosis or treatment with any form of glucocorticoids
• •Any form of diabetes (according to World Health Organization criteria)
• •Anaemia (haemoglobin below normal range)
• •Nephropathy (eGFR \<60 ml/min/1,73m2 and/or microalbuminuria)
• •Known liver disease and/or alanine transaminase (ALAT) or aspartate transaminase (ASAT) \>2 × upper normal limit
• •Any fractures within the last 6 months
• •For women: currently perimenopausal or postmenopausal
• •Diseases affecting calcium metabolism (e.g. hypoparathyroidism, hyperparathyroidism, osteoporosis, vitamin D deficiency and cancer)
• •Pregnancy or breastfeeding
• •Any condition considered incompatible with participation by the investigators